Does the media prefer OCUL or DRUG?

In the previous week, Ocular Therapeutix had 1 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 4 mentions for Ocular Therapeutix and 3 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 1.07 beat Ocular Therapeutix's score of 0.86 indicating that Bright Minds Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocular Therapeutix 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bright Minds Biosciences 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, TRLV or DRUG?

Trulieve Cannabis has higher revenue and earnings than Bright Minds Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Trulieve Cannabis $1.14B 2.07 N/A N/A N/A Bright Minds Biosciences N/A N/A -$8.74M -$2.08 N/A

Is TRLV or DRUG more profitable?

Trulieve Cannabis' return on equity of 0.00% beat Bright Minds Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Trulieve Cannabis N/A N/A N/A Bright Minds Biosciences N/A -12.46% -12.30%

Does the media refer more to TRLV or DRUG?

In the previous week, Trulieve Cannabis had 2 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 5 mentions for Trulieve Cannabis and 3 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 1.07 beat Trulieve Cannabis' score of 0.27 indicating that Bright Minds Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trulieve Cannabis 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bright Minds Biosciences 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor DRUG or PBH?

In the previous week, Bright Minds Biosciences and Bright Minds Biosciences both had 3 articles in the media. Bright Minds Biosciences' average media sentiment score of 1.07 beat Prestige Consumer Healthcare's score of 0.58 indicating that Bright Minds Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bright Minds Biosciences 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prestige Consumer Healthcare 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, DRUG or TRVI?

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Bright Minds Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bright Minds Biosciences N/A N/A -$8.74M -$2.08 N/A Trevi Therapeutics N/A N/A -$42.76M -$0.34 N/A

Is DRUG or TRVI more profitable?

Bright Minds Biosciences' return on equity of -12.46% beat Trevi Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Bright Minds Biosciences N/A -12.46% -12.30% Trevi Therapeutics N/A -23.59% -22.64%

Does the media favor DRUG or TRVI?

In the previous week, Bright Minds Biosciences and Bright Minds Biosciences both had 3 articles in the media. Trevi Therapeutics' average media sentiment score of 1.56 beat Bright Minds Biosciences' score of 1.07 indicating that Trevi Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bright Minds Biosciences 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Trevi Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer BHC or DRUG?

In the previous week, Bausch Health Cos had 4 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 7 mentions for Bausch Health Cos and 3 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 1.07 beat Bausch Health Cos' score of 0.91 indicating that Bright Minds Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch Health Cos 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bright Minds Biosciences 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Bright Minds Biosciences (DRUG) Competitors

$51.80 -1.71 (-3.20%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$51.86 +0.07 (+0.13%)

As of 09/25/2026 07:30 PM Eastern

Compare

DRUG vs. OCUL, TRLV, PBH, TRVI, and BHC

Should you buy Bright Minds Biosciences stock or one of its competitors? Bright Minds Biosciences's main competitors and comparable companies include Ocular Therapeutix (OCUL), Trulieve Cannabis (TRLV), Prestige Consumer Healthcare (PBH), Trevi Therapeutics (TRVI), and Bausch Health Cos (BHC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Bright Minds Biosciences compare to Ocular Therapeutix?

Ocular Therapeutix (NASDAQ:OCUL) and Bright Minds Biosciences (NASDAQ:DRUG) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, institutional ownership and risk.

Ocular Therapeutix currently has a consensus target price of $25.75, suggesting a potential upside of 166.84%. Bright Minds Biosciences has a consensus target price of $143.83, suggesting a potential upside of 177.67%. Given Bright Minds Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Bright Minds Biosciences is more favorable than Ocular Therapeutix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
Bright Minds Biosciences	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

Bright Minds Biosciences has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -579.10%. Bright Minds Biosciences' return on equity of -12.46% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocular Therapeutix	-579.10%	-59.89%	-45.99%
Bright Minds Biosciences	N/A	-12.46%	-12.30%

In the previous week, Ocular Therapeutix had 1 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 4 mentions for Ocular Therapeutix and 3 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 1.07 beat Ocular Therapeutix's score of 0.86 indicating that Bright Minds Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocular Therapeutix	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bright Minds Biosciences	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ocular Therapeutix has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market. Comparatively, Bright Minds Biosciences has a beta of -5.36, suggesting that its share price is 636% less volatile than the broader market.

Bright Minds Biosciences has lower revenue, but higher earnings than Ocular Therapeutix. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocular Therapeutix	$51.95M	40.80	-$265.94M	-$1.42	N/A
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.08	N/A

59.2% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are held by institutional investors. 3.1% of Ocular Therapeutix shares are held by company insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Bright Minds Biosciences beats Ocular Therapeutix on 8 of the 15 factors compared between the two stocks.

How does Bright Minds Biosciences compare to Trulieve Cannabis?

Trulieve Cannabis (NYSE:TRLV) and Bright Minds Biosciences (NASDAQ:DRUG) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

40.5% of Bright Minds Biosciences shares are held by institutional investors. 3.8% of Trulieve Cannabis shares are held by insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Trulieve Cannabis' return on equity of 0.00% beat Bright Minds Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trulieve Cannabis	N/A	N/A	N/A
Bright Minds Biosciences	N/A	-12.46%	-12.30%

Trulieve Cannabis presently has a consensus price target of $15.00, indicating a potential upside of 22.71%. Bright Minds Biosciences has a consensus price target of $143.83, indicating a potential upside of 177.67%. Given Bright Minds Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Bright Minds Biosciences is more favorable than Trulieve Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trulieve Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bright Minds Biosciences	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

In the previous week, Trulieve Cannabis had 2 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 5 mentions for Trulieve Cannabis and 3 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 1.07 beat Trulieve Cannabis' score of 0.27 indicating that Bright Minds Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trulieve Cannabis	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bright Minds Biosciences	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Trulieve Cannabis has higher revenue and earnings than Bright Minds Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trulieve Cannabis	$1.14B	2.07	N/A	N/A	N/A
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.08	N/A

Summary

Bright Minds Biosciences beats Trulieve Cannabis on 6 of the 10 factors compared between the two stocks.

How does Bright Minds Biosciences compare to Prestige Consumer Healthcare?

Bright Minds Biosciences (NASDAQ:DRUG) and Prestige Consumer Healthcare (NYSE:PBH) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Bright Minds Biosciences presently has a consensus target price of $143.83, suggesting a potential upside of 177.67%. Prestige Consumer Healthcare has a consensus target price of $67.67, suggesting a potential upside of 45.48%. Given Bright Minds Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Bright Minds Biosciences is more favorable than Prestige Consumer Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bright Minds Biosciences	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
Prestige Consumer Healthcare	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Prestige Consumer Healthcare has higher revenue and earnings than Bright Minds Biosciences. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.08	N/A
Prestige Consumer Healthcare	$1.09B	2.02	$190.30M	$3.57	13.03

40.5% of Bright Minds Biosciences shares are held by institutional investors. Comparatively, 100.0% of Prestige Consumer Healthcare shares are held by institutional investors. 42.7% of Bright Minds Biosciences shares are held by insiders. Comparatively, 1.5% of Prestige Consumer Healthcare shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Prestige Consumer Healthcare has a net margin of 15.57% compared to Bright Minds Biosciences' net margin of 0.00%. Prestige Consumer Healthcare's return on equity of 11.39% beat Bright Minds Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bright Minds Biosciences	N/A	-12.46%	-12.30%
Prestige Consumer Healthcare	15.57%	11.39%	5.66%

Bright Minds Biosciences has a beta of -5.36, meaning that its stock price is 636% less volatile than the broader market. Comparatively, Prestige Consumer Healthcare has a beta of 0.33, meaning that its stock price is 67% less volatile than the broader market.

In the previous week, Bright Minds Biosciences and Bright Minds Biosciences both had 3 articles in the media. Bright Minds Biosciences' average media sentiment score of 1.07 beat Prestige Consumer Healthcare's score of 0.58 indicating that Bright Minds Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bright Minds Biosciences	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Prestige Consumer Healthcare	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Prestige Consumer Healthcare beats Bright Minds Biosciences on 9 of the 14 factors compared between the two stocks.

How does Bright Minds Biosciences compare to Trevi Therapeutics?

Bright Minds Biosciences (NASDAQ:DRUG) and Trevi Therapeutics (NASDAQ:TRVI) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, valuation, dividends, risk and institutional ownership.

Bright Minds Biosciences' return on equity of -12.46% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bright Minds Biosciences	N/A	-12.46%	-12.30%
Trevi Therapeutics	N/A	-23.59%	-22.64%

Bright Minds Biosciences presently has a consensus target price of $143.83, suggesting a potential upside of 177.67%. Trevi Therapeutics has a consensus target price of $27.08, suggesting a potential upside of 87.95%. Given Bright Minds Biosciences' higher possible upside, equities analysts plainly believe Bright Minds Biosciences is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bright Minds Biosciences	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Bright Minds Biosciences has a beta of -5.36, meaning that its share price is 636% less volatile than the broader market. Comparatively, Trevi Therapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market.

In the previous week, Bright Minds Biosciences and Bright Minds Biosciences both had 3 articles in the media. Trevi Therapeutics' average media sentiment score of 1.56 beat Bright Minds Biosciences' score of 1.07 indicating that Trevi Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bright Minds Biosciences	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Trevi Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

40.5% of Bright Minds Biosciences shares are owned by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are owned by institutional investors. 42.7% of Bright Minds Biosciences shares are owned by insiders. Comparatively, 15.4% of Trevi Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Bright Minds Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.08	N/A
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.34	N/A

Summary

Trevi Therapeutics beats Bright Minds Biosciences on 7 of the 13 factors compared between the two stocks.

How does Bright Minds Biosciences compare to Bausch Health Cos?

Bausch Health Cos (NYSE:BHC) and Bright Minds Biosciences (NASDAQ:DRUG) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk.

Bausch Health Cos currently has a consensus price target of $8.00, indicating a potential upside of 40.47%. Bright Minds Biosciences has a consensus price target of $143.83, indicating a potential upside of 177.67%. Given Bright Minds Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Bright Minds Biosciences is more favorable than Bausch Health Cos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch Health Cos	1 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.14
Bright Minds Biosciences	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

Bright Minds Biosciences has a net margin of 0.00% compared to Bausch Health Cos' net margin of -10.12%. Bright Minds Biosciences' return on equity of -12.46% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch Health Cos	-10.12%	-561.95%	6.31%
Bright Minds Biosciences	N/A	-12.46%	-12.30%

Bausch Health Cos has a beta of 0.37, meaning that its stock price is 63% less volatile than the broader market. Comparatively, Bright Minds Biosciences has a beta of -5.36, meaning that its stock price is 636% less volatile than the broader market.

In the previous week, Bausch Health Cos had 4 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 7 mentions for Bausch Health Cos and 3 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 1.07 beat Bausch Health Cos' score of 0.91 indicating that Bright Minds Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch Health Cos	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bright Minds Biosciences	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

78.7% of Bausch Health Cos shares are owned by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are owned by institutional investors. 20.7% of Bausch Health Cos shares are owned by company insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Bausch Health Cos has higher revenue and earnings than Bright Minds Biosciences. Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch Health Cos	$10.85B	0.20	$157M	-$2.96	N/A
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.08	N/A

Summary

Bausch Health Cos and Bright Minds Biosciences tied by winning 8 of the 16 factors compared between the two stocks.

Get Bright Minds Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DRUG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DRUG vs. The Competition

Export

Metric	Bright Minds Biosciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$504.13M	$12.68B	$7.33B	$13.17B
Dividend Yield	N/A	2.63%	2.52%	14.04%
P/E Ratio	-24.90	797.38	275.82	25.78
Price / Sales	N/A	785.28	638.64	85.46
Price / Cash	N/A	89.30	79.52	52.89
Price / Book	6.22	10.54	10.44	6.30
Net Income	-$8.74M	$2.85B	$3.51B	$360.35M
7 Day Performance	-15.05%	-1.10%	-1.31%	-0.23%
1 Month Performance	-30.51%	-3.06%	-4.61%	-4.16%
1 Year Performance	-1.75%	1.28%	15.01%	4.58%

Bright Minds Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DRUG Bright Minds Biosciences	2.4271 of 5 stars	$51.80 -3.2%	$143.83 +177.7%	-1.7%	$504.13M	N/A	N/A	25	News Coverage Positive News High Trading Volume
OCUL Ocular Therapeutix	2.6768 of 5 stars	$10.19 -4.9%	$25.75 +152.7%	-23.0%	$2.24B	$51.95M	N/A	325	Positive News
TRLV Trulieve Cannabis	2.958 of 5 stars	$11.54 -0.7%	$15.00 +30.0%	N/A	$2.22B	N/A	N/A	5,000	News Coverage Short Interest Increase High Trading Volume
PBH Prestige Consumer Healthcare	3.2181 of 5 stars	$46.71 -1.9%	$70.75 +51.5%	-26.1%	$2.21B	$1.09B	13.09	890	News Coverage Analyst Forecast
TRVI Trevi Therapeutics	3.1977 of 5 stars	$15.04 -5.3%	$27.08 +80.1%	+64.3%	$2.14B	N/A	N/A	34	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DRUG) was last updated on 9/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bright Minds Biosciences (DRUG) Competitors

DRUG vs. OCUL, TRLV, PBH, TRVI, and BHC

How does Bright Minds Biosciences compare to Ocular Therapeutix?

Summary

How does Bright Minds Biosciences compare to Trulieve Cannabis?

Summary

How does Bright Minds Biosciences compare to Prestige Consumer Healthcare?

Summary

How does Bright Minds Biosciences compare to Trevi Therapeutics?

Summary

How does Bright Minds Biosciences compare to Bausch Health Cos?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRUG vs. The Competition

Bright Minds Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bright Minds Biosciences (DRUG) Competitors

DRUG vs. OCUL, TRLV, PBH, TRVI, and BHC

How does Bright Minds Biosciences compare to Ocular Therapeutix?

Do analysts recommend OCUL or DRUG?

Is OCUL or DRUG more profitable?

Does the media prefer OCUL or DRUG?

Which has more volatility & risk, OCUL or DRUG?

Which has higher valuation & earnings, OCUL or DRUG?

Do insiders and institutionals hold more shares of OCUL or DRUG?

Summary

How does Bright Minds Biosciences compare to Trulieve Cannabis?

Do insiders and institutionals have more ownership in TRLV or DRUG?

Is TRLV or DRUG more profitable?

Do analysts rate TRLV or DRUG?

Does the media refer more to TRLV or DRUG?

Which has higher earnings and valuation, TRLV or DRUG?

Summary

How does Bright Minds Biosciences compare to Prestige Consumer Healthcare?

Do analysts prefer DRUG or PBH?

Which has better earnings & valuation, DRUG or PBH?

Do insiders & institutionals believe in DRUG or PBH?

Is DRUG or PBH more profitable?

Which has more volatility & risk, DRUG or PBH?

Does the media favor DRUG or PBH?

Summary

How does Bright Minds Biosciences compare to Trevi Therapeutics?

Is DRUG or TRVI more profitable?

Do analysts prefer DRUG or TRVI?

Which has more volatility and risk, DRUG or TRVI?

Does the media favor DRUG or TRVI?

Do insiders and institutionals have more ownership in DRUG or TRVI?

Which has higher earnings & valuation, DRUG or TRVI?

Summary

How does Bright Minds Biosciences compare to Bausch Health Cos?

Do analysts recommend BHC or DRUG?

Is BHC or DRUG more profitable?

Which has more risk & volatility, BHC or DRUG?

Does the media prefer BHC or DRUG?

Do insiders and institutionals believe in BHC or DRUG?

Which has higher valuation and earnings, BHC or DRUG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DRUG vs. The Competition

Bright Minds Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools